



New and Emerging Target-Oriented Drugs for Atopic Dermatitis

Guest Editor:

Prof. Dr. Tiago Torres

1. Department of Dermatology,
Centro Hospitalar Universitário
do Porto, Porto, Portugal
2. Instituto de Ciências
Biomédicas Abel Salazar,
University of Porto, Porto,
Portugal

Deadline for manuscript
submissions:

closed (28 February 2023)

Message from the Guest Editor

Dear Colleagues,

Atopic dermatitis (AD) is a clinically heterogeneous inflammatory skin condition that has a great impact on patients' daily activities that remains difficult to treat. The pathophysiology of AD is thought to be a result of the interaction between various critical factors, such as epidermal barrier disruption, genetic susceptibility, activation of distinct subsets of T-cells, environmental triggers, and dysbiosis of commensal skin microbiota.

The knowledge acquired over the last decade on AD pathophysiology has led to the development of new targeted therapeutic options, including biologic agents and small molecules, that enable clinicians to better manage AD patients. The main therapeutic targets include cytokines related to Th2 inflammation and their intracellular JAK-STAT signalling pathway, but many other agents (topical, oral, and parenteral drugs) with different targets are in the pipeline.

This Special Issue aims to review recent and future therapy development for the treatment of atopic dermatitis.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma